Published in Metabolites on October 10, 2012
Proteomic and metabonomic biomarkers for hepatocellular carcinoma: a comprehensive review. Br J Cancer (2015) 1.01
Can NMR solve some significant challenges in metabolomics? J Magn Reson (2015) 0.98
Targeted metabolic profiling of hepatocellular carcinoma and hepatitis C using LC-MS/MS. Electrophoresis (2013) 0.94
Hepatocellular carcinoma: Review of disease and tumor biomarkers. World J Hepatol (2016) 0.94
Metabolomics method to comprehensively analyze amino acids in different domains. Analyst (2015) 0.81
Metabolic Characterization of Advanced Liver Fibrosis in HCV Patients as Studied by Serum 1H-NMR Spectroscopy. PLoS One (2016) 0.79
Biomarker Discovery and Translation in Metabolomics. Curr Metabolomics (2016) 0.77
The Plasma and Serum Metabotyping of Hepatocellular Carcinoma in a Nigerian and Egyptian Cohort using Proton Nuclear Magnetic Resonance Spectroscopy. J Clin Exp Hepatol (2017) 0.75
Hepatocellular carcinoma. N Engl J Med (2011) 19.40
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature (2009) 12.58
Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med (1995) 5.55
Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology (2008) 4.73
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Metabolomics: a global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol (2008) 3.48
Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol (2002) 2.94
Metabolomics-based methods for early disease diagnostics. Expert Rev Mol Diagn (2008) 2.51
Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med (2003) 2.51
Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol (2009) 2.33
A review of chemical issues in 1H NMR spectroscopy: N-acetyl-L-aspartate, creatine and choline. NMR Biomed (1991) 2.12
Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J Proteome Res (2009) 2.10
Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. Gut (2011) 1.98
Muscle creatine loading in men. J Appl Physiol (1985) (1996) 1.88
Metabolomics in human nutrition: opportunities and challenges. Am J Clin Nutr (2005) 1.85
Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol Cell Proteomics (2011) 1.81
Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. Cancer Res (2011) 1.67
Early detection of recurrent breast cancer using metabolite profiling. Cancer Res (2010) 1.61
Application of 1H NMR-based metabonomics in the study of metabolic profiling of human hepatocellular carcinoma and liver cirrhosis. Cancer Sci (2009) 1.60
Metabonomics: NMR spectroscopy and pattern recognition analysis of body fluids and tissues for characterisation of xenobiotic toxicity and disease diagnosis. Curr Opin Chem Biol (2003) 1.57
Choline transport for phospholipid synthesis. Exp Biol Med (Maywood) (2006) 1.56
Early stage diagnosis of oral cancer using 1H NMR-based metabolomics. Neoplasia (2009) 1.50
Metabonomics study of liver cancer based on ultra performance liquid chromatography coupled to mass spectrometry with HILIC and RPLC separations. Anal Chim Acta (2009) 1.50
Metabonomic studies of human hepatocellular carcinoma using high-resolution magic-angle spinning 1H NMR spectroscopy in conjunction with multivariate data analysis. J Proteome Res (2007) 1.47
Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clin Cancer Res (2010) 1.42
Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Res (2002) 1.40
Diagnosis of hepatocellular carcinoma. World J Gastroenterol (2009) 1.39
Diagnosis of liver cancer using HPLC-based metabonomics avoiding false-positive result from hepatitis and hepatocirrhosis diseases. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 1.35
Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am J Gastroenterol (2004) 1.32
Phospholipid metabolism in cancer cells monitored by 31P NMR spectroscopy. J Biol Chem (1987) 1.32
Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of urine. J Proteome Res (2010) 1.30
Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry. Anal Chim Acta (2009) 1.28
The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer (1998) 1.27
Esophageal cancer metabolite biomarkers detected by LC-MS and NMR methods. PLoS One (2012) 1.20
Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res (2011) 1.18
A serum metabolomic investigation on hepatocellular carcinoma patients by chemical derivatization followed by gas chromatography/mass spectrometry. Rapid Commun Mass Spectrom (2008) 1.18
Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. Am J Gastroenterol (1998) 1.11
Identification of serum biomarkers of hepatocarcinoma through liquid chromatography/mass spectrometry-based metabonomic method. Anal Bioanal Chem (2011) 1.07
Metabolomic investigation of gastric cancer tissue using gas chromatography/mass spectrometry. Anal Bioanal Chem (2009) 1.06
Characterization of urinary biomarkers of hepatocellular carcinoma using magnetic resonance spectroscopy in a Nigerian population. J Proteome Res (2010) 1.03
Metabolomic profiling of serum from human pancreatic cancer patients using 1H NMR spectroscopy and principal component analysis. Appl Biochem Biotechnol (2011) 1.03
Serum alpha-fetoprotein levels in acute viral hepatitis. Gut (1973) 1.02
In vivo proton magnetic resonance spectroscopy of large focal hepatic lesions and metabolite change of hepatocellular carcinoma before and after transcatheter arterial chemoembolization using 3.0-T MR scanner. J Magn Reson Imaging (2004) 1.01
Metabolomics study of esophageal adenocarcinoma. J Thorac Cardiovasc Surg (2010) 0.99
Extracellular levels of amino acids and choline in human high grade gliomas: an intraoperative microdialysis study. Neurochem Res (2004) 0.94
Predictive value of tumor markers for hepatocarcinogenesis in patients with hepatitis C virus. J Gastroenterol (2010) 0.94
Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of blood plasma. J Proteome Res (2011) 0.93
Gas chromatography/mass spectrometry screening of serum metabolomic biomarkers in hepatitis B virus infected cirrhosis patients. Clin Chem Lab Med (2009) 0.87
Secreted ERBB3 isoforms are serum markers for early hepatoma in patients with chronic hepatitis and cirrhosis. J Proteome Res (2011) 0.86
The valine catabolic pathway in human liver: effect of cirrhosis on enzyme activities. Hepatology (1996) 0.85
31P NMR studies of cultured human tumor cells. Influence of pH on phospholipid metabolite levels and the detection of cytidine 5'-diphosphate choline. NMR Biomed (1990) 0.81
Human liver disease decreases methacrylyl-CoA hydratase and beta-hydroxyisobutyryl-CoA hydrolase activities in valine catabolism. Clin Chim Acta (2001) 0.79